Latest Press Releases

Il vaccino Pfizer-BioNTech BNT162b2 (Comirnaty) offre una protezione moderata dalla variante Omicron nei bambini dai 5 agli 11 anni

30 Jun, 2022

Padova, 30 giugno 2022 Il vaccino Pfizer-BioNTech BNT162b2 (Comirnaty) offre una protezione moderata dalla variante Omicron nei bambini dai 5…
Read More

Study reveals moderate effectiveness of Pfizer Covid-19 vaccine against Omicron in children aged 5-11

30 Jun, 2022

Padua, 30 June 2022 – A large study on the effectiveness of the Pfizer Covid-19 vaccine in children aged 5-11…
Read More

GARDP study reveals that babies are increasingly dying of neonatal sepsis caused by drug-resistant bacterial infections

26 Apr, 2022

Geneva, 26 April 2022 – A large study focusing on newborn babies with clinically diagnosed sepsis has revealed the impact…
Read More

Uno studio di GARDP rivela che i neonati muoiono sempre più frequentemente per sepsi neonatale causata da infezioni batteriche resistenti ai farmaci

26 Apr, 2022

Ginevra, 26 Aprile 2022 – Un importante studio sui neonati ha rivelato l’impatto della resistenza agli antibiotici sulla sepsi neonatale,…
Read More

MEDIA CENTRE

More Information

About Penta

Penta is an international independent scientific network dedicated to child health. Our work is the result of a passionate collaboration between healthcare professionals and researchers in more than 110 centres across 31 countries around the world. Through our studies and partnerships, we develop and deliver world-class research and training in paediatric infectious diseases to improve the lives of women and children, wherever they live.

Find out more

Annual reports

You can download the latest annual report or read our previous reports for detailed information on our strategy and research findings.

Read our reports

Media inquiries

We welcome members of the press to contact our Communications team at communication@pentafoundation.org or by phone +39 3486151202 with any media-related inquires or interview requests.

 

Social Media